Group 1 - The company, Jiangsu Jibeier Pharmaceutical Co., Ltd., has received the approval notice for the listing application of the chemical raw material drug Gatifloxacin from the National Medical Products Administration [1][2] - Gatifloxacin is a broad-spectrum antibacterial drug effective against various bacteria, including Gram-positive and Gram-negative bacteria, and is the main raw material for the company's Gatifloxacin eye drops [2] - The approval is valid until October 21, 2030, and the company is required to continue accumulating research data on nitrosamine impurities and improve control strategies as necessary [2] Group 2 - The approved Gatifloxacin raw material is primarily used to meet the production needs of the company's Gatifloxacin eye drops, and it is not expected to have a significant impact on the company's recent operations [3]
江苏吉贝尔药业股份有限公司自愿披露关于收到化学原料药上市申请批准通知书的公告